alopecia

Posts

Global Alopecia (Hair Loss Treatment) Market

Global Alopecia Market

Global Alopecia (Hair Loss Treatment) Market

Industry Growth Insights published new data on the “Alopecia (Hair Loss Treatment) Market”. The research report is titled “Alopecia (Hair Loss Treatment) Market research by Types (Shampoos and Conditioners, Medicine Product), By Applications (Men, Women), By Players/Companies Shiseido, Rohto, Unilever, Taisho, Angfa, LOreal, Kaminomoto, Merck, Yanagiya Honten, Amorepacific, Procter & Gamble, Himalaya, Gerolymatos International, Merz Pharma, Leader Teck, Vasu Healthcare, VLCC, Ales Group, Shanxi Ante, Wansheng Pharmaceutical, Advanced Skin and Hair, Humanwell Healthcare, Topfond, Lifes2good, Bawang, YNK Pharmaceutical, Apollo, Jingxiutang, Rogaine, Marico”. As per the latest research Alopecia (Hair Loss Treatment) market is expected to expand at a CAGR of xx% in the forecast period.

Scope Of The Report

Report Attributes
Report DetailsReport Title

Alopecia (Hair Loss Treatment) Market Research Report

By Type

Shampoos and Conditioners, Medicine Product

By Application

Men, Women

By Companies

Shiseido, Rohto, Unilever, Taisho, Angfa, LOreal, Kaminomoto, Merck, Yanagiya Honten, Amorepacific, Procter & Gamble, Himalaya, Gerolymatos International, Merz Pharma, Leader Teck, Vasu Healthcare, VLCC, Ales Group, Shanxi Ante, Wansheng Pharmaceutical, Advanced Skin and Hair, Humanwell Healthcare, Topfond, Lifes2good, Bawang, YNK Pharmaceutical, Apollo, Jingxiutang, Rogaine, Marico

Regions Covered

North America, Europe, APAC, Latin America, MEA

Base Year

2020

Historical Year

2018 to 2019 (Data from 2010 can be provided as per availability)

Forecast Year

Global Alopecia (Hair Loss Treatment) Industry Outlook

Global Alopecia (Hair Loss Treatment) Market Report Segments:

The global Alopecia (Hair Loss Treatment) market is segmented on the basis of:

Types

Shampoos and Conditioners, Medicine Product

The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights into the market. Furthermore, it discusses the latest product developments & innovation in the market.

Applications

Men, Women

The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and the driving and restraining factors of each application segment.

Some of the companies that are profiled in this report are:

Shiseido
Rohto
Unilever
Taisho
Angfa
LOreal
Kaminomoto
Merck
Yanagiya Honten
Amorepacific
Procter & Gamble
Himalaya
Gerolymatos International
Merz Pharma
Leader Teck
Vasu Healthcare
VLCC
Ales Group
Shanxi Ante
Wansheng Pharmaceutical
Advanced Skin and Hair
Humanwell Healthcare
Topfond
Lifes2good
Bawang
YNK Pharmaceutical
Apollo
Jingxiutang
Rogaine
Marico

Global Alopecia (Hair Loss Treatment) Market Overview

Highlights of The Alopecia (Hair Loss Treatment) Market Report:

The market structure and projections for the coming years.
Drivers, restraints, opportunities, and current trends of Alpha Hydroxy Acid for Cosmetic Market.
Historical data and forecast.
Estimations for the forecast period 2028.
Developments and trends in the market.
By Type:

Shampoos and Conditioners
Medicine Product

By Application:

Men
Women

Market scenario by region, sub-region, and country.
Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
Government Policies, Macro & Micro economic factors are also included in the report.

We have studied the Alopecia (Hair Loss Treatment) Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2028.

Regional Analysis

North America
Europe
Asia Pacific
Middle East & Africa
Latin America

Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.

The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.

How you may use our products:

Correctly Positioning New Products
Market Entry Strategies
Business Expansion Strategies
Consumer Insights
Understanding Competition Scenario
Product & Brand Management
Channel & Customer Management
Identifying Appropriate Advertising Appeals

Global Alopecia (Hair Loss Treatment) Market Statistics

 

8 Reasons to Buy This Report

Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
Implemented Robust Methodology to Prepare the Report
Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
Provides Information About the Top-winning Strategies Implemented by Industry Players.
In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
Customization of the Report Available

Global Alopecia (Hair Loss Treatment) Market

Source

Recent Posts

Global Alopecia (Hair Loss Treatment) Market

Global Alopecia Market

Global Alopecia (Hair Loss Treatment) Market

Industry Growth Insights published new data on the “Alopecia (Hair Loss Treatment) Market”. The research report is titled “Alopecia (Hair Loss Treatment) Market research by Types (Shampoos and Conditioners, Medicine Product), By Applications (Men, Women), By Players/Companies Shiseido, Rohto, Unilever, Taisho, Angfa, LOreal, Kaminomoto, Merck, Yanagiya Honten, Amorepacific, Procter & Gamble, Himalaya, Gerolymatos International, Merz Pharma, Leader Teck, Vasu Healthcare, VLCC, Ales Group, Shanxi Ante, Wansheng Pharmaceutical, Advanced Skin and Hair, Humanwell Healthcare, Topfond, Lifes2good, Bawang, YNK Pharmaceutical, Apollo, Jingxiutang, Rogaine, Marico”. As per the latest research Alopecia (Hair Loss Treatment) market is expected to expand at a CAGR of xx% in the forecast period.

Scope Of The Report

Report Attributes
Report DetailsReport Title

Alopecia (Hair Loss Treatment) Market Research Report

By Type

Shampoos and Conditioners, Medicine Product

By Application

Men, Women

By Companies

Shiseido, Rohto, Unilever, Taisho, Angfa, LOreal, Kaminomoto, Merck, Yanagiya Honten, Amorepacific, Procter & Gamble, Himalaya, Gerolymatos International, Merz Pharma, Leader Teck, Vasu Healthcare, VLCC, Ales Group, Shanxi Ante, Wansheng Pharmaceutical, Advanced Skin and Hair, Humanwell Healthcare, Topfond, Lifes2good, Bawang, YNK Pharmaceutical, Apollo, Jingxiutang, Rogaine, Marico

Regions Covered

North America, Europe, APAC, Latin America, MEA

Base Year

2020

Historical Year

2018 to 2019 (Data from 2010 can be provided as per availability)

Forecast Year

Global Alopecia (Hair Loss Treatment) Industry Outlook

Global Alopecia (Hair Loss Treatment) Market Report Segments:

The global Alopecia (Hair Loss Treatment) market is segmented on the basis of:

Types

Shampoos and Conditioners, Medicine Product

The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights into the market. Furthermore, it discusses the latest product developments & innovation in the market.

Applications

Men, Women

The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and the driving and restraining factors of each application segment.

Some of the companies that are profiled in this report are:

Shiseido
Rohto
Unilever
Taisho
Angfa
LOreal
Kaminomoto
Merck
Yanagiya Honten
Amorepacific
Procter & Gamble
Himalaya
Gerolymatos International
Merz Pharma
Leader Teck
Vasu Healthcare
VLCC
Ales Group
Shanxi Ante
Wansheng Pharmaceutical
Advanced Skin and Hair
Humanwell Healthcare
Topfond
Lifes2good
Bawang
YNK Pharmaceutical
Apollo
Jingxiutang
Rogaine
Marico

Global Alopecia (Hair Loss Treatment) Market Overview

Highlights of The Alopecia (Hair Loss Treatment) Market Report:

The market structure and projections for the coming years.
Drivers, restraints, opportunities, and current trends of Alpha Hydroxy Acid for Cosmetic Market.
Historical data and forecast.
Estimations for the forecast period 2028.
Developments and trends in the market.
By Type:

Shampoos and Conditioners
Medicine Product

By Application:

Men
Women

Market scenario by region, sub-region, and country.
Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
Government Policies, Macro & Micro economic factors are also included in the report.

We have studied the Alopecia (Hair Loss Treatment) Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2028.

Regional Analysis

North America
Europe
Asia Pacific
Middle East & Africa
Latin America

Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.

The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.

How you may use our products:

Correctly Positioning New Products
Market Entry Strategies
Business Expansion Strategies
Consumer Insights
Understanding Competition Scenario
Product & Brand Management
Channel & Customer Management
Identifying Appropriate Advertising Appeals

Global Alopecia (Hair Loss Treatment) Market Statistics

 

8 Reasons to Buy This Report

Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
Implemented Robust Methodology to Prepare the Report
Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
Provides Information About the Top-winning Strategies Implemented by Industry Players.
In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
Customization of the Report Available

Global Alopecia (Hair Loss Treatment) Market

Source

Recent Posts

CTP-543 for Alopecia Areata

CTP-543 for Alopecia Areata

Concert Pharmaceuticals Initiates THRIVE-AA2 Phase 3 Clinical Trial Evaluating CTP-543 for Alopecia Areata

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced it has initiated THRIVE-AA2, the second planned Phase 3 clinical trial to evaluate the efficacy and safety of CTP-543, an oral Janus kinase inhibitor, in adult patients with moderate to severe alopecia areata. The Company expects to report topline results from THRIVE-AA2 in the second half of 2022. Under current timelines, the Company believes that positive results from two Phase 3 trials could serve as the basis for submitting a New Drug Application to the U.S. Food and Drug Administration (FDA) in early 2023 for CTP-543 for the treatment of moderate to severe alopecia areata in adult patients.

“We expect the CTP-543 THRIVE-AA clinical program to provide the pivotal data needed to support our registration,” said James V. Cassella, Ph.D., Chief Development Officer of Concert Pharmaceuticals. “The continued support of the alopecia areata community has been essential in progressing our program, and the initiation of this second Phase 3 trial brings us another step closer to seeking FDA-approval. We are hopeful that CTP-543 will be one of the first FDA-approved treatments for alopecia areata and will offer an important therapeutic option for this challenging autoimmune disease.”

“Alopecia areata can bring disruption and burden to daily life. But with the progress of clinical trials, there’s hope for patients,” said Thea Chassin, the Founder and Chief Executive Officer of Bald Girls Do Lunch Inc., an alopecia areata advocacy, education and support nonprofit. “We’re grateful for Concert’s research on behalf of the alopecia areata community. We applaud Concert’s goal to develop a potential new medication.”

About the THRIVE-AA2 Study

THRIVE-AA2 (NCT04797650) is a randomized, double-blind, placebo-controlled clinical trial in adult patients with moderate to severe alopecia areata at sites in the U.S., Canada and Europe evaluating the regrowth of scalp hair after 24 weeks of dosing using the Severity of Alopecia Tool (SALT). Key aspects of THRIVE-AA2 include:

  • Patient characteristics: adults age 18-65 years with ≥ 50% hair loss are eligible for the study;
  • Expected enrollment size: approximately 440 patients;
  • Dosing: 8 mg or 12 mg of CTP-543 or placebo twice-daily for 24 weeks; and
  • Primary endpoint: Percent of patients achieving a SALT score ≤ 20 at Week 24.

For more information about the THRIVE-AA1 and THRIVE-AA2 studies, please visit www.clinicaltrials.gov.

About CTP-543 and Alopecia Areata

CTP-543 is an oral selective inhibitor of Janus kinases JAK1 and JAK2. The FDA has granted CTP-543 Breakthrough Therapy designation for the treatment of adult patients with moderate to severe alopecia areata and Fast Track designation for the treatment of alopecia areata.

Alopecia areata is an autoimmune disease in which the immune system attacks hair follicles, resulting in partial or complete loss of hair on the scalp and body. Alopecia areata may affect up to 1 million Americans at any given time1. The scalp is the most commonly affected area, but any hair-bearing site can be affected alone or together with the scalp. The onset of the disease can occur throughout life and affects both women and men. Alopecia areata can be associated with serious psychological consequences, including anxiety and depression. There are currently no drugs approved by the FDA for the treatment of alopecia areata.

The FDA selected alopecia areata as one of eight new disease areas that it focused on under its Patient-Focused Drug Development Initiative (PFDDI) in 2016-2017. The goal of the PFDDI is to bring patient perspectives into an earlier stage of product development. Following the FDA’s Patient-Focused Drug Development meeting held in September 2017 on alopecia areata, the FDA summarized the input shared by patients and patient representatives in a Voice of the Patient report. Additional information on the PFDDI is available online.

About Concert

Concert Pharmaceuticals is a clinical stage biopharmaceutical company that is developing small molecule drugs that it discovered through the application of its DCE Platform® (deuterated chemical entity platform). Selective incorporation of deuterium into known molecules has the potential, on a case-by-case basis, to provide better pharmacokinetic or metabolic properties, thereby enhancing their clinical safety, tolerability or efficacy. Concert’s lead product candidate is in late-stage development for the treatment of alopecia areata, a serious autoimmune dermatological condition. Concert is also assessing a number of earlier-stage pipeline candidates.

Concert Pharmaceuticals Initiates THRIVE-AA2 Phase 3 Clinical Trial Evaluating CTP-543 for Alopecia Areata

Source

Recent Posts

Global Alopecia Treatment Market

Alopecia Treatment Market

Global Alopecia Treatment Market Research Report 2021-2027

The research team projects that the Alopecia Treatment market size will grow from XXX in 2020 to XXX by 2027, at an estimated CAGR of XX. The base year considered for the study is 2020, and the market size is projected from 2020 to 2027.

The prime objective of this alopecia report is to help the user understand the market in terms of its definition, segmentation, market potential, influential trends, and the challenges that the market is facing with 10 major regions and 50 major countries.

Deep researches and analysis were done during the preparation of the report. The readers will find this report very helpful in understanding the market in depth. The data and the information regarding the market are taken from reliable sources such as websites, annual reports of the companies, journals, and others and were checked and validated by the industry experts.

The facts and data are represented in the report using diagrams, graphs, pie charts, and other pictorial representations. This enhances the visual representation and also helps in understanding the facts much better.

By Market Players:

Teva Pharmaceutical Industries

Merck

Johnson&Johnson

Reddy`s Laboratories

Cipla

Cellmid

Himalaya Drug

Taisho Pharmaceutical Holdings

By Type

Topical Drugs

Oral Drugs

Injectable

Hair Transplant Services

Other

By Application

Hospitals

Dermatology And Trichology Clinics

Home Care Settings

Other

By Regions/Countries:

North America

United States

Canada

Mexico

East Asia

China

Japan

South Korea

Europe

Germany

United Kingdom

France

Italy

Russia

Spain

Netherlands

Switzerland

Poland

South Asia

India

Pakistan

Bangladesh

South East Asia

Indonesia

Thailand

Singapore

Malaysia

Philippines

Vietnam

Myanmar

Middle East

Turkey

Saudi Arabia

Iran

United Arab Emirates

Israel

Iraq

Qatar

Kuwait

Oman

Africa

Nigeria

South Africa

Egypt

Algeria

Morocoo

Oceania

Australia

New Zealand

South America

Brazil

Argentina

Colombia

Chile

Venezuela

Peru

Puerto Rico

Ecuador

Rest of the World

Kazakhstan

Points Covered in The Report

The points that are discussed within the report are the major market players that are involved in the market such as market players, raw material suppliers, equipment suppliers, end users, traders, distributors and etc.

The complete profile of the companies is mentioned. And the capacity, production, price, revenue, cost, gross, gross margin, sales volume, sales revenue, consumption, growth rate, import, export, supply, future strategies, and the technological developments that they are making are also included within the report. This report analyzed 12 years of data history and forecast.

The growth factors of the market is discussed in detail wherein the different end users of the market are explained in detail.

Data and information by market player, by region, By Type, By Application and etc, and custom research can be added according to specific requirements.

The report contains the SWOT analysis of the market. Finally, the report contains the conclusion part where the opinions of the industrial experts are included.

Key Reasons to Purchase

To gain insightful analyses of the market and have a comprehensive understanding of the global market and its commercial landscape.

Assess the production processes, major issues, and solutions to mitigate the development risk.

To understand the most affecting driving and restraining forces in the market and its impact in the global market.

Learn about the market strategies that are being adopted by leading respective organizations.

To understand the future outlook and prospects for the market.

Besides the standard structure reports, we also provide custom research according to specific requirements.

The report focuses on Global, Top 10 Regions and Top 50 Countries Market Size of Alopecia Treatment 2016-2021, and development forecast 2022-2027 including industries, major players/suppliers worldwide and market share by regions, with company and product introduction, position in the market including their market status and development trend By Types and applications which will provide its price and profit status, and marketing status & market growth drivers and challenges, with base year as 2020.

Key Indicators Analysed

Market Players & Competitor Analysis: The report covers the key players of the industry including Company Profile, Product Specifications, Production Capacity/Sales, Revenue, Price and Gross Margin 2016-2021 & Sales by Product Types.

Global and Regional Market Analysis: The report includes Global & Regional market status and outlook 2022-2027. Further, the report provides break down details about each region & countries covered in the report. Identifying its production, consumption, import & export, sales volume & revenue forecast.

Market Analysis by Product Type: The report covers the majority of Product Types in the Alopecia Treatment Industry, including its product specifications by each key player, volume, sales by Volume and Value (M USD).

Market Analysis By Application Type: Based on the Alopecia Treatment Industry and its applications, the market is further sub-segmented into several major Application of its industry. It provides you with the market size, CAGR & forecast by each industry applications.

Market Trends: Market key trends include Increased Competition and Continuous Innovations.

Opportunities and Drivers: Identifying the Growing Demands and New Technology

Porters Five Force Analysis: The report will provide the state of competition in the industry depends on five basic forces: the threat of new entrants, bargaining power of suppliers, bargaining power of buyers, the threat of substitute products or services, and existing industry rivalry.

Global Alopecia Treatment Market Research Report 2021-2027

Source

Recent Posts

Global Alopecia Treatment Market

Androgenic Alopecia Market Size

Androgenic Alopecia Drug Market Size

Up Market Research offers the latest published report on “Global Global Androgenic Alopecia Drug Market Research Report 2019 Market Research Report 2019” delivering key insights and providing a competitive advantage to clients through a detailed report. The report highly exhibits on current market analysis scenario, upcoming as well as future opportunities, revenue growth, pricing and profitability.

Global Androgenic Alopecia Drug Market Research Report 2019 Market research report delivers a close watch on leading competitors with strategic analysis, micro and macro market trend and scenarios, pricing analysis and a holistic overview of the market situations in the forecast period.

It is a professional and detailed report focusing on primary and secondary drivers, market share, leading segments and geographical analysis. Further, key players, major collaborations, merger & acquisitions along trending innovation and business policies are reviewed in the report. The report contains basic, secondary and advanced information pertaining to the Global Androgenic Alopecia Drug Market Research Report 2019

Market global status and trend, market size, share, growth, trends analysis, segment and forecasts from 2019 – 2026.

The report for Global Androgenic Alopecia Drug Market Research Report 2019 Market analysis & forecast 2019 – 2026 is segmented into Product Segment, Application Segment & Major players.

Region-wise Analysis Global Androgenic Alopecia Drug Market Research Report 2019 Market covers:

• North America
• Europe
• China
• Japan
• India
• Southeast Asia
• Other regions (Central & South America, Middle East & Africa)

The Global Androgenic Alopecia Drug Market Research Report 2019 Market Report can be segmented into Product Types and Applications.

The Report Covers In-Depth Analysis As Follows:

• Chapter 1 Overview of Global Androgenic Alopecia Drug Market Research Report 2019 Market
• Chapter 2 Global Market Status and Forecast by Regions
• Chapter 3 Global Market Status and Forecast by Types
• Chapter 4 Global Market Status and Forecast by Downstream Industry
• Chapter 5 Market Driving Factor Analysis of Global Androgenic Alopecia Drug Market Research Report 2019 Market
• Chapter 6 Global Androgenic Alopecia Drug Market Research Report 2019 Market Competition Status by Major Manufacturers
• Chapter 7 Global Androgenic Alopecia Drug Market Research Report 2019 Market Major Manufacturers Introduction and Market Data
• Chapter 8 Upstream and Downstream Market Analysis of Global Androgenic Alopecia Drug Market Research Report 2019 Market
• Chapter 9 Cost and Gross Margin Analysis of Global Androgenic Alopecia Drug Market Research Report 2019 Market
• Chapter 10 Marketing Status Analysis of Global Androgenic Alopecia Drug Market Research Report 2019 Market
• Chapter 11 Report Conclusion
• Chapter 12 Research Methodology and Reference

“Global Androgenic Alopecia Drug Market Research Report 2019 Market Analysis and Forecast 2019 – 2026” report helps the clients to take business decisions and to understand the strategies of major players in the industry.

The report also calls for market-driven results deriving feasibility studies for client needs. UpMarketResearch ensures qualified and verifiable aspects of market data operating in the real-time scenario. The analytical studies are conducted ensuring client needs with a thorough understanding of market capacities in the real-time scenario.

Global Androgenic Alopecia Drug Market Research Report 2019 Market: Key Stakeholders:

• Manufacturers
• Distributors/Traders/Wholesalers
• Subcomponent Manufacturers
• Industry Association
• Downstream Vendors

In this study, the years considered to estimate the market size of the Global Androgenic Alopecia Drug Market Research Report 2019 Market are as follows:

• History Year: 2013-2018
• Base Year: 2018
• Estimated Year: 2019
• Forecast Year 2019 to 2026

Key Reasons to Purchase:

• To gain insightful analyses of the market and have a comprehensive understanding of the “Global Androgenic Alopecia Drug Market Research Report 2019 Market” and its commercial landscape.
• Learn about the market strategies that are being adopted by your competitors and leading organizations.
• To understand the future outlook and prospects for Global Androgenic Alopecia Drug Market Research Report 2019 Market analysis and forecast 2019 – 2026.

Androgenic Alopecia Drug Market Size

Source

Recent Posts

Global Alopecia Treatment Market

Alopecia Market Scenario Globally

Global Statistics Representing Alopecia Market Scenario Globally

Globally, the prevalence of alopecia, such as androgenetic alopecia and alopecia areata, is increasing at a concerning rate. This can be attributed to the rising consumption of unhealthy food, sedentary lifestyle, genetic factors, hormonal imbalance, rising healthcare expenditure, increasing chronic diseases, surging geriatric population, rising disposable incomes, and high focus on aesthetic appearance.

As per the American Hair Loss Association, globally, around 95% of men face hair loss, and over 8, 00,000 people seek treatment for the same. For the record, alopecia is also common in women, and about one-third of women are suffering from androgenetic alopecia across the globe.

Moreover, women suffering from postmenopausal and Polycystic Ovary Syndrome (PCOS) are more likely to develop hair thinning and bald spots adoption of surgical hair transplant and scalp treatments. To attend to the situation, several leading players are actively working to develop novel therapeutic drugs and are heavily investing in R&D activities for the same. For instance, the introduction of fast-acting JAK inhibitors, and PRP treatment is driving the market growth.

Segmental Insights

The global alopecia market is segmented into disease type, end-user, sales channels, and gender.

Alopecia Areata to Witness Significant Growth

By disease type, the alopecia market is further segmented into cicatricial alopecia, alopecia totalis, areata, androgenetic alopecia, Universalis, and among others. The alopecia areata segment is expected to witness significant growth during the forecast period on account of the surging prevalence of a number of diseases, such as diabetes, hyperthyroidism, and Down’s syndrome. Moreover, alopecia totalis and Universalis are the advanced stages of alopecia areata.

The androgenetic alopecia is the fastest-growing segment. It is majorly driven by the launch of pipeline drugs and the increasing prevalence of diseases. It is majorly caused among the individuals associated with a genetic predisposition to hair loss. To attend to the situation, a number of treatment options have been developed by the leading players, including finasteride and minoxidil, licensed topical treatment, and surgical treatment like hair transplant.

Dermatology Clinics to Dominate the Market

By the end-user, the alopecia market is segmented into dermatology, clinics, home care settings, and others.

The dermatology clinics segment is dominating the alopecia market and will continue the same during the forecast period. This can be attributed to the rising number of hair restoration and transplantation surgeries across the globe. The clinic segment is expected to hold a significant share in the market on account of the rising availability of technologically advanced therapies, robust healthcare infrastructure, and growing demand for single session hair restoration procedures across the globe. On 13th May 2019, Bosley and Hair Club announced the launch of BioGraft. The groundbreaking treatment incorporates both surgical and non-surgical hair restoration for rapid transformation and is now available to patients across the globe.

The home care settings segment is majorly driven by the rising number of regulatory approvals for home-use devices, increasing adoption of laser therapy for hair loss treatment, technological advancements, and availability of innovative devices. The laser combs segment is grabbing the highest shares in the home care setting segment as it reduces pain, aids in fast healing, remove the blockage, improves blood circulation, ensures oxygen supply to the scalp, aids in cell replacement, and increases the strength, shine, and elasticity of hair.

Over the Counter Products to Lead the Market

By sales channel, the alopecia market is bifurcated into prescription-based and over the counter (OTC) products. The over the counter products segment is leading the alopecia market. This can be accredited to the growing demand for low-cost treatment and the availability of alternatives. Additionally, a surge in the number of FDA approval for OTC hair loss treatment products is adding fuel to the market growth. For instance, recently, the FDA approved ‘Keranique’ hair regrowth serum and ‘Oscar Blandi hair lift’ serum for instant thickening and strengthening of hair.

By Gender, Alopecia to be More Prevalent in Men than Women

As per the American Hair Loss Association and the U.S. National Library of Medicine, around 50% of men experience hair fall at the age of 50. Moreover, the surge in the geriatric population and high tobacco intake among men is driving the market growth. For the record, some men also experience hair loss in the teens and early twenties due to fluctuating hormones. Whereas, around 40% of the women experience hair loss at the age of 50. Women with menopause are more likely to suffer from hair loss due to a drop in hormone levels. However, alopecia is not permanent in women and can be caused due to stress.

Regional Insights

North America to Dominate the Alopecia Market

North America is dominating the alopecia market on account of increasing advancements in the healthcare infrastructure, availability of novel therapeutics treatment options, rising healthcare expenditure, and high disposable income. As per the U.S. National Library Health Medicine, 1 out of 1000 Americans suffers from alopecia. According to IMS Health, currently, there are around 9,600 dermatologists and about 7,800 dermatology clinics across the U.S. that are arduously working to attend to the situation.

Asia Pacific to be the Fastest Growing Market

Asia Pacific is the fastest growing alopecia market and is expected to grow at a CAGR of 6.9% during the forecast period. This can be attributed to the availability of advanced treatment options and increasing spending power in emerging economies, such as Singapore, India, and China. Moreover, the consumer base in the region prefers traditional alopecia therapy, which includes oil massage and hair masks. In South Korea, China, Japan, and India, the aesthetic drugs are witnessing huge popularity and are anticipated to drive the market growth to some extent.  Other factors driving the market include the rising prevalence of alopecia areata and several skin-related disorders, increasing population, rising incidence of chronic diseases, and changing lifestyle.

South America

South America’s alopecia market is anticipated to reach USD 34.7 million by 2023. Argentina is the fastest growing market in South America on account of the rising geriatric population and sedentary lifestyle. The country is also adopting hair loss treatment and has surpassed a volume of around 52,000 hair loss treatment products in 2017. The region is backed by the presence of leading players that are actively working in the field to sustain in the raging competition. Currently, the players are focusing on developing herbal and natural ingredients to promote hair growth. Furthermore, Brazil is expected to witness significant growth during the forecast period. This can be attributed to the increasing demand for hair care products containing both active and medicinal ingredients.

The Middle East and Africa to Offer Significant Opportunities in the Coming Years

The Middle East and Africa will offer lucrative growth opportunities in the alopecia market during the forecast period owing to increasing technological advancements, rising healthcare expenditures, growing support by the government, and advancement in healthcare facilities.

Competitive Landscape: Market Moving Towards Consolidation

The global alopecia market is highly fragmented in nature, with different market players operating in local regions. Some of the key players are engaging in acquisitions, collaborations, and partnerships to gain a competitive edge. For instance, Johnson & Johnson Consumer, Inc. collaborated with the University of Pennsylvania to design improved preclinical models for the study of human hair growth and androgenetic alopecia. On 6th July 2016,  Alpecin has expanded its footprint in the China market. The alopecia market is consolidated with the presence of Kirkland Signature Vitabiotics, Sun Pharma, Merck & Co., Dr. Reddy’s Laboratories, Cipla, Johnson & Johnson, Alpecin, Phyto Ales Group, and Lifes2good.

Alopecia Market Segmentation

By Disease Type

  • Cicatricial Alopecia
  • Alopecia Totalis
  • Areata
  • Androgenetic Alopecia
  • Universalis
  • Others

By End-User

  • Dermatology
  • Clinics
  • Homecare Settings
  • Others

By Sales Channels

  • Prescription-Based
  • Over the Counter (OTC) Products

By Region

  • Americas
  • Europe
  • AsiaPacific
  • MEA

Global Statistics Representing Alopecia Market Scenario Globally

Source

Recent Posts

Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies

PRP and Stem cell alopecia

U.S. PRP and Stem cell alopecia treatment Market Report Overview

U.S. PRP and Stem cell alopecia treatment market garnered a revenue of USD 129.4 million in the year 2019 globally and is anticipated to reach USD 189.2 million by 2027, growing at a compound annual growth (CAGR) of 4.9% over the forecast period.

The market has been observed to be growing at a steady growth rate over the last three years, however, with the impact of the COVID-19 pandemic globally, the business conditions are expected to change. The market size may reduce significantly or increase with a spike depending on how the value chain has been affected in the entire process.

Players that are operational in the market for a longer period of time are anticipated to absorb the sudden changes, losses and increased operational costs better than those who have recently entered the market.

The report focuses on numerous factors that are anticipated to impact the market growth directly and indirectly. The report categorically analyses the growth patterns of different segments based on multiple derivation models.

Both the qualitative and quantitative aspects have been covered under the report. The U.S. PRP & Stem cell alopecia treatment market report includes market size, drivers, restraints, opportunities and trends that will help you understand the market dynamics in detail.

Moreover, the report will include market estimates & forecasts in terms of revenue for the overall market along with the segments mentioned in the study. The report focuses on providing a holistic view of the entire market scenario from multiple unmatched detailed analysis mentioned in the report.

What to expect from the report?

  • U.S. PRP and Stem cell alopecia treatment Total Available Market (TAM)Size
  • U.S. PRP and Stem cell alopecia treatment Serviceable Available Market (SAM) Size
  • Business Implications of COVID-19 on the Overall Market
  • Market Share/ Revenue Share (%) of Top Market Players in Total Market Size (2019)
  • Market Size & Forecast (2016-2027) At Country & Regional Level, By Segments
  • Overview & Analysis of Key Players Operating in the Market

Key Highlights:

COVID-19 – Impact of COVID-19 on overall business scenario

U.S. PRP and Stem cell alopecia treatment Market Revenue 2020

Global market revenue in 2020 will be derived taking into various micro & macro-level factors; along with the COVID-19 pandemic

Competitive Analysis Company Market Share Analysis, 2019 (%)

Supply Chain Analysis – Analysis pertaining to several participants of the supply chain such as raw material suppliers, distributors, & OEMs along with others will be highlighted in the study

Data Source Primary & Secondary Research, Internal DataBase & Company Annual Reports

Regions Included North America,

Countries Included U.S., Canada,

U.S. PRP and Stem cell alopecia treatment Market Report Overview

Source

Recent Posts

Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies

Stem Cell and Platelet Rich Plasma Alopecia Therapies

COVID-19 Impact on Global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Size, Status and Forecast 2020-2026t

This report focuses on the global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

The key players covered in this study

Orange County Hair Restoration Center
Hair Sciences Center of Colorado
Anderson Center for Hair
Evolution Hair Loss Institute
Savola Aesthetic Dermatology Center
Virginia Surgical Center
Hair Transplant Institute of Miami
Colorado Surgical Center & Hair Institute

Market segment by Type, the product can be split into

Platelet Rich Plasma Injections
Stem Cell Therapy
Market segment by Application, split into
Dermatology Clinics
Hospitals

Market segment by Regions/Countries, this report covers

North America
Europe
China
Japan
Southeast Asia
India
Central & South America

The study objectives of this report are:

To analyze global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies status, future forecast, growth opportunity, key market and key players.
To present the Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies are as follows:

History Year: 2015-2019
Base Year: 2019
Estimated Year: 2020
Forecast Year 2020 to 2026

For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Summary:

Get the latest Market Research Reports on COVID-19 Impact on Global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies. Industry analysis & Market Report on COVID-19 Impact on Global Stem

Cell and Platelet Rich Plasma (PRP) Alopecia Therapies is a syndicated market report, published as COVID-19 Impact on Global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Size,

Status and Forecast 2020-2026. It is a complete Research Study and Industry Analysis of COVID-19 Impact on Global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market, to understand,

Market Demand, Growth, trends analysis and Factor Influencing market.

COVID-19 Impact on Global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Size, Status and Forecast 2020-2026

Source

Recent Posts

Hair Regrowth in Phase 3 Alopecia Areata

Hair Regrowth in Phase 3 Alopecia Areata

Baricitinib is First JAK-Inhibitor to Demonstrate Hair Regrowth in Phase 3 Alopecia Areata (AA) Trial

Eli Lilly and Company announced today top-line results from BRAVE-AA2, a Phase 3 study evaluating the efficacy and safety of once-daily baricitinib 2-mg and 4-mg in adults with severe alopecia areata (AA).

Both doses of baricitinib met the primary efficacy endpoint at Week 36, demonstrating a statistically significant improvement in scalp hair regrowth compared to those randomized to placebo. AA is an autoimmune disease that causes patchy hair loss on the scalp, face and sometimes on other areas of the body that can progress.

Baricitinib has received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for the treatment of AA. This classification aims to expedite the development and review of drugs that are intended to treat a serious condition when preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over already available therapies on a clinically significant endpoint(s). There are currently no FDA-approved treatments for AA.

“These positive results are very promising and suggest that baricitinib has the potential to address the urgent needs of people living with alopecia areata,” said Brett King, M.D., Ph.D., associate professor of Dermatology at Yale School of Medicine. “This level of high-quality research is needed to advance our understanding and the treatment of this frequently devastating disease.”

This multicenter, randomized, double-blind, placebo-controlled study included 546 adults with a Severity of Alopecia Tool (SALT) score ≥ 50 (i.e., who had ≥50% scalp hair loss) and a current episode of severe AA lasting at least six months but no more than eight years. The study included a diverse patient population from Argentina, Australia, Brazil, China, Israel, Japan, South Korea, Taiwan and the U.S.

Safety outcomes of baricitinib in BRAVE-AA2 were consistent with its established safety profile in patients with rheumatoid arthritis (RA) and atopic dermatitis (AD). No deaths, major adverse cardiovascular events (MACE) or venous thromboembolic events (VTEs) were reported in the study.

BRAVE-AA2 is the first Phase 3 study with positive results in patients with AA. Data from an additional Phase 3 study of baricitinib in AA will be available in the first half of this year. Detailed results from the BRAVE program will be presented at an upcoming medical conference and published in a peer-reviewed journal later this year. AA is the second potential treatment indication in dermatology for baricitinib after AD.

“For patients who suffer from alopecia areata, it is not a cosmetic condition, it is a devastating autoimmune disease that can have significant psychological effects. They lose much more than just hair,” said Lotus Mallbris, M.D., Ph.D., vice president of immunology development at Lilly. “We are looking forward to sharing the totality of data from the overall clinical development program for baricitinib as a potential first-in-disease treatment for alopecia areata.”

“Significant unmet need exists in the treatment of alopecia areata,” said Abby Ellison, research director at the National Alopecia Areata Foundation (NAAF). “We appreciate Lilly’s important work in this area and are excited that these data could bring us closer to a potential new treatment option for patients.”

Baricitinib is an oral JAK inhibitor discovered by Incyte and licensed to Lilly. It is approved and commercially available as OLUMIANT in the U.S. and more than 70 countries as a treatment for adults with moderate to severe active RA and in the European Union and Japan for the treatment of adult patients with moderate to severe AD who are candidates for systemic therapy. Baricitinib is also being investigated in systematic lupus erythematosus (SLE), juvenile idiopathic arthritis (JIA) and COVID-19.

Baricitinib is First JAK-Inhibitor to Demonstrate Hair Regrowth in Phase 3 Alopecia Areata (AA) Trial

Source

Recent Posts

Global Alopecia Treatment Market

Speaker discusses use of JAK inhibitors in alopecia

Speaker discusses use of JAK inhibitors in alopecia

A speaker at South Beach Symposium Medical Dermatology Summit discussed the JAK inhibitors that are currently on the market and their applications in treating alopecia areata.

Antonella Tosti, MD, said that JAK inhibitors “are probably the future of treatment for alopecia areata.”

Of the three main JAK inhibitors used for alopecia areata — ruxolitinib, baricitinib and tofacitinib — tofacitinib “has been most studied,” Tosti said. The standard dose of tofacitinib is 5 mg twice daily.

Patients usually regrow hair about 3 months after beginning treatment, and even though some patients may take longer, they should “persist and continue the treatment,” she said.

About 70% of patients respond to tofacitinib, although it is typically less effective in long-standing alopecia totalis or alopecia universalis. However, the oral formulation is more effective than the topical formulation, Tosti said.

Large clinical trials for ruxolitinib and baricitinib are ongoing, according to Tosti. In the literature cited during the presentation, ruxolitinib doses were 10 mg twice daily and 10 mg every other day. She also said “usually ruxolitinib causes visible regrowth earlier than tofacitinib.”

There is not yet data on long-term side effects, but patients commonly experience upper respiratory infections, headache and weight gain. Given the potential danger of upper respiratory infections during the era of COVID-19, Tosti has advised her patients to discontinue treatment if they develop COVID-19 symptoms. Other side effects, such as severe infection, have been reported among patients taking a JAK inhibitor for another indication.

Tosti said there are several JAK inhibitor compounds in the phase 2 or 3 stage of development.

Speaker discusses use of JAK inhibitors in alopecia

Source

Recent Posts

Global Alopecia Treatment Market

Study Results for the Treatment of Androgenic Alopecia

Histogen Announces Week 26 HST-001 Study Results for the Treatment of Androgenic Alopecia in Men

Histogen today announced week 26 results from its Phase 1b/2a clinical trial of HST-001 in male patients with androgenic alopecia. At the week 26 timepoint, patients treated with HST-001 demonstrated a statistically significant change from baseline in total hairs (terminal and vellus) in the target area (TAHC) in the vertex as measured by Canfield’s Hairmetrix macrophotography system.

HST-001 was also shown to be safe and well-tolerated at week 26 as compared to placebo with no reports of serious adverse events. Similar to the week 18 primary endpoint results we reported in December of 2020, HST-001 did not achieve statistical significance at week 26 when compared to placebo.

“The recently completed study demonstrated that HST-001 was safe, well-tolerated, and exhibited signals of efficacy. This data will inform future development, and I look forward to working with Histogen and our other expert advisors as we plan and execute the next study in men with androgenetic alopecia,” said Dr Stacy Smith, M.D., founder of the California Dermatology and Clinical Research Institution and principal investigator for the HST-001 trial.

“We are encouraged that these results demonstrated that patients treated with HST-001 grow both terminal and vellus hairs in men with androgenic alopecia,” said Richard W. Pascoe, Histogen’s President and CEO. “Moreover, 84% of the subjects who received HST-001 responded to treatment over the 26-week period and the study drug was found to be safe and well-tolerated across all subjects.

With this data in hand, we have begun planning for a more substantive clinical trial in men with androgenic alopecia with the goal of determining the best clinical pathway for future registration trials. We anticipate the trial will commence in the second half of 2021.”

About the HST-001 Phase 1a/2b Study
This 2:1 randomized, blinded, the placebo-controlled, single-site study enrolled 36 male patients with androgenic alopecia with mild to moderate hair loss on a Norwood-Hamilton (N-H) Scale (3V, 4, 5), with a total of 30 evaluable patients at week 26.

It was designed to assess the safety and tolerability of HST-001, as well as indicators of efficacy at weeks 18 and 26. The primary study endpoint is an absolute change from baseline versus week 18 in total hairs (terminal and vellus) in the (TAHC) of the vertex as measured by Canfield’s Hairmetrix macrophotography system.

Secondary endpoints include absolute change from baseline in total hairs (terminal and vellus) new terminal and vellus hair count, hair thickness density and per cent change from baseline in TAHC, terminal and vellus hair counts in the vertex and right temporal regions at weeks 18 and 26, all as measured by Canfield’s Hairmetrix macrophotography system. At each treatment time point (Weeks 0, 6 and 12), patients received a total of 20 injections, 10 in the vertex scalp region and 5 in each temporal region for a total dose of 2mL.

About HST-001
HST-001, or Hair Stimulating Complex (HSC), is intended to be a physician-administered therapeutic for hair loss. HSC is anticipated to be a relatively safe, minimally invasive treatment that promotes new hair growth where existing treatments only reduce hair loss. HSC is manufactured to enrich for growth factors including KGF, VEGF and follistatin, which are involved in signaling stem cells in the body and have been shown to be important in hair formation and the stimulation of resting hair follicles.

About Histogen
Histogen Inc. is a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function.

Histogen’s innovative technology platform utilizes cell conditioned media and extracellular matrix materials produced by hypoxia-induced multipotent cells. Histogen’s proprietary, reproducible manufacturing process provides targeted solutions across a broad range of therapeutic indications including hair growth, dermal rejuvenation, joint cartilage regeneration and spinal disk repair.

For more information, please visit www.histogen.com.

Histogen Announces Week 26 HST-001 Study Results for the Treatment of Androgenic Alopecia in Men

Source

Recent Posts